Niagen Bioscience Inc

Análisis de la acción Niagen Bioscience Inc (NAGE)

$3.290

+0.082 (+2.49%)Al cierre

Loading chart…
High
3.303
Open
3.220
VWAP
3.26
Vol
498.29K
Mkt Cap
Low
3.200
Amount
1.63M
EV/EBITDA, TTM
35.70

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities.

AI analysis of Niagen Bioscience Inc (NAGE)

buy

Niagen Bioscience, Inc. appears to be a good buy right now due to its current price of $3.29, which is significantly lower than the analyst price target of $10, suggesting a potential upside of over 200%. Additionally, the company has a strong gross margin of 64.84% and a recent RSI of 63.87, indicating positive momentum. However, the main risk is the recent decline in revenue, with a year-to-date change of -47.36%.

Métricas de valoración

The current forward P/E ratio for Niagen Bioscience Inc (NAGE) is 23.58, compared to its 5-year average forward P/E of 42.29.

Forward P/E

Fair
5Y Average P/E
42.29
Current P/E
23.58
Sobrevalorada
69.28
Infravalorada
15.31

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
30.29
Current EV/EBITDA
35.70
Sobrevalorada
44.05
Infravalorada
16.52

Forward P/S

Undervalued
5Y Average P/S
3.72
Current P/S
1.64
Sobrevalorada
5.52
Infravalorada
1.91

Alphio AI Price Scenarios for NAGE

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NAGE

$14.51

Precio del escenario

B

Base

Base · 50%NAGE

$12.61

Precio del escenario

B

Bear

Bear · 25%NAGE

$10.88

Precio del escenario

Whales holding NAGE

S

SteelPeak Wealth, LLC

+ HoldingNAGE

-3.05%

3M Return

Cronología de eventos

2026-08-20 (ET)

09:00:00

Niagen Bioscience's Tru Niagen Now Available at GNC and Sam's Club

2026-08-12 (ET)

10:00:00

Niagen Bioscience CFO Discusses NAD Strategy and Future Developments

2026-08-06 (ET)

14:30:00

Niagen Bioscience CFO Discusses Company Strategy and New Ventures

2026-08-03 (ET)

09:00:00

Niagen Bioscience Selects Evotec to Support NB4168 Development

2026-07-28 (ET)

09:00:00

Niagen Bioscience Publishes New Study Analysis

Noticias

NAGE FAQ — answered by Alphio AI

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities. It operates in the Healthcare sector.

Niagen Bioscience, Inc. appears to be a good buy right now due to its current price of $3.29, which is significantly lower than the analyst price target of $10, suggesting a potential upside of over 200%. Additionally, the company has a strong gross margin of 64.84% and a recent RSI of 63.87, indicating positive momentum. However, the main risk is the recent decline in revenue, with a year-to-date change of -47.36%.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis